Morphic Therapeutic
Signal active
Organization
Contact Information
Overview
Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. The company offers the development of therapies for patients with immunological, fibrotic, neoplastic, and vascular diseases, focusing on creating small molecule inhibitors of various integrin targets.
About
Industries
Biotechnology, Health Care, Medical, Therapeutics
Founded
2015
Employees
101-250
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Morphic Therapeutic headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $40.8B in funding across 80 round(s). With a team of 101-250 employees, Morphic Therapeutic is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Morphic Therapeutic, raised $51.5M. Discover more about their projects, partnerships, and impact on our platform.
Employees
Funding Rounds
Funding rounds
5
Investors
8
Lead Investors
0
Total Funding Amount
$510.5M
Details
3
Morphic Therapeutic has raised a total of $510.5M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 80.0M | ||
| 2016 | Seed | 3.0M | ||
| 2016 | Early Stage Venture | 51.5M |
Investors
Morphic Therapeutic is funded by 32 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Schrödinger | - | FUNDING ROUND - Schrödinger | 51.5M |
| ShangPharma | - | FUNDING ROUND - ShangPharma | 51.5M |
| Morphic Therapeutic | - | FUNDING ROUND - Morphic Therapeutic | 51.5M |
| Timothy A. Springer | - | FUNDING ROUND - Timothy A. Springer | 51.5M |
Recent Activity
There is no recent news or activity for this profile.